{"url_path":"/sec/rigl/8-k/2026-05-20/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1034842/0001034842-26-000041-index.html","accession_number":"0001034842-26-000041","cik":"0001034842","ticker":"RIGL","issuer_name":"RIGEL PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1034842/0001034842-26-000041-index.html","primary_entity_key":"0001034842","primary_entity_name":"RIGEL PHARMACEUTICALS INC"},"word_count":298,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nThe following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is set forth in the Proxy Statement.\n\nElection of Directors\n\nEach of the nominees for director, to serve until the Company’s 2029 Annual Meeting of Stockholders or until his or her respective successor has been elected and qualified, was elected as follows:\n\nName of DirectorForWithheldAbstainBroker Non-Votes\n\nAlison Hannah, M.D.9,202,113 1,469,709 49,583 3,406,029 \n\nWalter Moos, Ph.D.10,436,673 242,736 41,996 3,406,029 \n\nRaul Rodriguez10,486,503 192,614 42,288 3,406,029 \n\nApproval of the Amended 2018 Equity Incentive Plan\n\nThe Company’s stockholders approved the Amended 2018 Equity Incentive Plan.\n\nForAgainstAbstainBroker Non-Votes\n\n6,497,964 3,813,701 409,740 3,406,029 \n\nApproval of the 2000 Employee Stock Purchase Plan\n\nThe Company’s stockholders approved the Amended 2000 Employee Stock Purchase Plan.\n\nForAgainstAbstainBroker Non-Votes\n\n9,840,922 475,464 405,019 3,406,029 \n\nSay-on-Pay\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement.\n\nForAgainstAbstainBroker Non-Votes\n\n9,013,480 1,291,609 416,316 3,406,029 \n\nRatification of Selection of Ernst & Young\n\nThe Company’s stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.\n\nForAgainstAbstainBroker Non-Votes\n\n12,590,773 1,506,852 29,809 — \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\nDated: May 20, 2026\nRIGEL PHARMACEUTICALS, INC.\n\nBy:/s/ Raymond J. Furey\n\nRaymond J. Furey\n\nExecutive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary"}